WO2008041244A3 - A method for the identification of potential biomarkers and drug targets in brain plasticity related disorders - Google Patents

A method for the identification of potential biomarkers and drug targets in brain plasticity related disorders Download PDF

Info

Publication number
WO2008041244A3
WO2008041244A3 PCT/IN2007/000452 IN2007000452W WO2008041244A3 WO 2008041244 A3 WO2008041244 A3 WO 2008041244A3 IN 2007000452 W IN2007000452 W IN 2007000452W WO 2008041244 A3 WO2008041244 A3 WO 2008041244A3
Authority
WO
WIPO (PCT)
Prior art keywords
related disorders
drug targets
potential biomarkers
identification
brain plasticity
Prior art date
Application number
PCT/IN2007/000452
Other languages
French (fr)
Other versions
WO2008041244A2 (en
WO2008041244B1 (en
Inventor
Abhay Sharma
Priyanka Singh
Farhan, Md
Original Assignee
Council Scient Ind Res
Abhay Sharma
Priyanka Singh
Farhan, Md
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res, Abhay Sharma, Priyanka Singh, Farhan, Md filed Critical Council Scient Ind Res
Priority to EP07827592A priority Critical patent/EP2076608A2/en
Publication of WO2008041244A2 publication Critical patent/WO2008041244A2/en
Publication of WO2008041244A3 publication Critical patent/WO2008041244A3/en
Publication of WO2008041244B1 publication Critical patent/WO2008041244B1/en
Priority to NO20091627A priority patent/NO20091627L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to identification of potential biomarkers and drug targets in brain plasticity related disorders. In particular, the invention describes a system level model of brain plasticity related disorders in the fruit fly Drosophila melanogaster, thereby identifying potential biomarkers and drug targets in epileptogenesis and associated conditions. The invention also provides a means of screening therapeutic agents against epilepsy and related disorders using gene expression profiling in Drosophila.
PCT/IN2007/000452 2006-10-05 2007-10-01 A method for the identification of potential biomarkers and drug targets in brain plasticity related disorders WO2008041244A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07827592A EP2076608A2 (en) 2006-10-05 2007-10-01 A method for the identification of potential biomarkers and drug targets in brain plasticity related disorders
NO20091627A NO20091627L (en) 2006-10-05 2009-04-23 Procedure for Identifying Potential Biomarkers and Drug Templates in Brain Plasticity-Related Disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2193DE2006 2006-10-05
IN2193/DEL/2006 2006-10-05

Publications (3)

Publication Number Publication Date
WO2008041244A2 WO2008041244A2 (en) 2008-04-10
WO2008041244A3 true WO2008041244A3 (en) 2008-07-31
WO2008041244B1 WO2008041244B1 (en) 2008-10-09

Family

ID=39198212

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2007/000452 WO2008041244A2 (en) 2006-10-05 2007-10-01 A method for the identification of potential biomarkers and drug targets in brain plasticity related disorders

Country Status (3)

Country Link
EP (1) EP2076608A2 (en)
NO (1) NO20091627L (en)
WO (1) WO2008041244A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108977549B (en) * 2018-07-04 2021-01-15 中国农业大学 Primer pair for detecting expression quantity of CG5210 gene of fruit fly

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291739B1 (en) * 2000-03-24 2001-09-18 Council Of Scientific And Industrial Research Method for screening of potential anti-epileptic drugs using a Drosophila melanogaster model

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291739B1 (en) * 2000-03-24 2001-09-18 Council Of Scientific And Industrial Research Method for screening of potential anti-epileptic drugs using a Drosophila melanogaster model

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CEPELAK I ET AL: "Valproate and carbamazepine comedication changes hepatic enzyme activities in sera of epileptic children", CLINICA CHIMICA ACTA 19980828 NL, vol. 276, no. 2, 28 August 1998 (1998-08-28), pages 121 - 127, XP002477701, ISSN: 0009-8981 *
GU J ET AL: "The antiepileptic drug levetiracetam selectively modifies kindling-induced alterations in gene expression in the temporal lobe of rats", EUROPEAN JOURNAL OF NEUROSCIENCE, OXFORD UNIVERSITY PRESS, GB, vol. 19, no. 2, January 2004 (2004-01-01), pages 334 - 345, XP002324334, ISSN: 0953-816X *
HASSEL BJORNAR ET AL: "Changes in gene expression suggest new mechanisms of long-term valproate treatment.", EPILEPSIA, vol. 44, no. Supplement 9, 2003, & ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY; BOSTON, MA, USA; DECEMBER 05-10, 2003, pages 338 - 339, XP009099234, ISSN: 0013-9580 *
JEONG M R ET AL: "Profiles of valproate - regulated gene expression in mouse brain.", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 2003, 2003, & 33RD ANNUAL MEETING OF THE SOCIETY OF NEUROSCIENCE; NEW ORLEANS, LA, USA; NOVEMBER 08-12, 2003, pages Abstract No. 850.3 URL - http://sf, XP009099218 *
KIM SEUNG-KI ET AL: "Gene expression profile analyses of cortical dysplasia by cDNA arrays.", EPILEPSY RESEARCH, vol. 56, no. 2-3, October 2003 (2003-10-01), pages 175 - 183, XP002477728, ISSN: 0920-1211 *
KUEBLER DANIEL ET AL: "Anticonvulsant valproate reduces seizure-susceptibility in mutant Drosophila.", BRAIN RESEARCH, vol. 958, no. 1, 20 December 2002 (2002-12-20), pages 36 - 42, XP002477727, ISSN: 0006-8993 *
KUMAR KIRAN ET AL: "Erythrocyte glutathione and serum total glutathione-S-transferase in epilepsy.", CLINICAL CHEMISTRY AND LABORATORY MEDICINE : CCLM / FESCC 2005, vol. 43, no. 1, 2005, pages 106 - 107, XP009099236, ISSN: 1434-6621 *
STILWELL GEOFF E ET AL: "Development of a Drosophila seizure model for in vivo high-throughput drug screening", EUROPEAN JOURNAL OF NEUROSCIENCE, vol. 24, no. 8, October 2006 (2006-10-01), pages 2211 - 2222, XP002477726, ISSN: 0953-816X *
ZUSTERZEEL PETRA L M ET AL: "Glutathione S-transferase alpha levels in epileptic and healthy women preconceptionally and throughout pregnancy", GYNECOLOGIC AND OBSTETRIC INVESTIGATION, vol. 48, no. 2, August 1999 (1999-08-01), pages 89 - 92, XP009099237, ISSN: 0378-7346 *

Also Published As

Publication number Publication date
NO20091627L (en) 2009-07-02
WO2008041244A2 (en) 2008-04-10
WO2008041244B1 (en) 2008-10-09
EP2076608A2 (en) 2009-07-08

Similar Documents

Publication Publication Date Title
EP1755654A4 (en) Methods and systems for treatment of neurological diseases of the central nervous system
EP1951910A4 (en) Identification of genetic polymorphic variants associated with somatosensory disorders and methods of using the same
DE602006009543D1 (en) SYSTEM FOR AV INTERVAL SELECTION IN AN IMPLANTABLE MEDICINE PRODUCT
WO2009132656A3 (en) Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
WO2010118035A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
ATE452883T1 (en) CRYSTALLINE FORM OF 1-CHLORINE-4-(ß-D-GLUCOPYRANOS-1-YL)-2-Ä4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYLUBENZENE, METHOD FOR THE PRODUCTION THEREOF AND ITS USE FOR THE PRODUCTION OF MEDICATIONS
ZA200705900B (en) Identification system and method for medication management
EP1906980A4 (en) Method of treatment or management of stress
EP1824384A4 (en) System and method for diagnosis of brainstem disorders
WO2010014990A3 (en) Method of promoting neurogenesis by modulating secretase activities
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2007092535A3 (en) 4-acylaminopyridine derivative mediated neurogenesis
WO2009015369A3 (en) Isophthalamide derivatives inhibiting beta-secretase activity
WO2007002080A3 (en) Eya2s as modifiers of the pten/akt pathway and methods of use
WO2006089009A3 (en) Methods and compositions for the treatment of lipid-associated disorders
GB0403490D0 (en) Screening methods
WO2008041244A3 (en) A method for the identification of potential biomarkers and drug targets in brain plasticity related disorders
WO2006009962A3 (en) Acacs as modifiers of the igf pathway and methods of use
WO2006129867A3 (en) ENHANCED EXPRESSION OF LACTOFERRIN mRNA BY LACRITIN
WO2012061808A3 (en) Neuropsychiatric test reports
WO2005016279A3 (en) Melks as modifiers of the rac pathway and methods of use
WO2010054324A3 (en) Methods for treating clinical conditions associated with lipoprotein lipase activity
WO2005072241A3 (en) Inhibition of bright function as a treatment for excessive immunoglobulin production
WO2008021432A3 (en) Compositions and methods for treatment of conditions affecting the nervous system
WO2008021015A3 (en) Methods of making esters of camptothecins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07827592

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007827592

Country of ref document: EP